MCK is the nation’s largest pharmaceutical distributor, providing supplies and services to hospitals, retail pharmacies, and medical offices through four business lines: U.S. pharmaceutical, prescription technology solutions, medical-surgical solutions, and international. In its second-quarter fiscal 2027 earnings report, MCK showed $111 billion in revenue (an 8% year-over-year gain) led by North American pharmaceutical ($91.4 billion) and GLP-1 distribution ($16 billion), an operating profit of $1.9 billion (a 13% rise), adjusted per-share earnings of $11.68 (an 18% jump), and full-year EPS guidance of up to $46.40 (implies 19% growth).
It’s no wonder MCK shares are up 32% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.
Institutions Love McKesson
Institutional volumes reveal plenty. In the last year, MCK has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in MCK shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with McKesson.
McKesson Fundamental Analysis
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, MCK has had strong sales and earnings growth:
- 3-year sales growth rate (+13.4%)
- 3-year EPS growth rate (+17.7%)
Source: FactSet
Also, EPS is estimated to ramp higher this year by +14.3%.
Now it makes sense why the stock has been generating Big Money interest. MCK has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
McKesson has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s drawn multiple outlier inflow signals, gaining 235.5% since the one on May 10, 2022. The blue bars below show when MCK was a top pick on the Outlier 20 report in the last five years…Big Money loves this stock:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
McKesson Price Prediction
The MCK action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in MCK at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.